Data as of Sep 30, 2026, 6:36 AM

Sara Bailey is a Republican Director, Office of National Drug Control Policy who disclosed 5 STOCK Act trades from Feb 1, 2026 to Mar 1, 2026.
Executive 278-T trades via Open Cabinet (OGE periodic transaction reports)
Trades
5
Purchases
4
Sales
1
Tickers
3
Est. volume
$40.0k
$32.0k buy · $8,001 sell
Avg. filing delay
—
Filed after 45 days
—
Estimated disclosed stock book
$11.7k
Educated guesstimate from STOCK Act size ranges, not net worth.
Estimated P/L
-$4,715
Guesstimate from disclosed size ranges.
| Traded issuer | Sector | Type | Size | Traded | Trade price | Yesterday | Published | Filed after |
|---|---|---|---|---|---|---|---|---|
Fidelity Advisor Biotechnology Fund Class C SharesFBTCX | Financial Services | Purchase | $1k–$15k | Mar 1, 2026 | $29.71 | $35.74 | Mar 1, 2026 | — |
| Traded issuer | Sector | Type | Size | Traded | Trade price | Yesterday | Published | Filed after |
|---|---|---|---|---|---|---|---|---|
Byrna Technologies Inc. Common StockBYRN | Equity | Purchase | $1k–$15k | Mar 1, 2026 | $12.78 | $3.33 | Mar 1, 2026 | — |
Fidelity Advisor Biotechnology Fund Class C SharesFBTCX | Financial Services | Purchase | $1k–$15k | Mar 1, 2026 | $29.71 | $35.74 | Mar 1, 2026 | — |
GE Verona | Unclassified | Purchase | $1k–$15k | Mar 1, 2026 | — | — | Mar 1, 2026 | — |
TMC the metals company Inc. Common StockTMC | Equity | Sale | $1k–$15k | Mar 1, 2026 | $6.27 | $3.74 | Mar 1, 2026 | — |
TMC the metals company Inc. Common StockTMC | Equity | Purchase | $1k–$15k | Feb 1, 2026 | $6.62 | $3.74 | Feb 1, 2026 | — |
Download Sara Bailey trades (CSV)All disclosed rows for this filer in the current snapshot. Amounts are STOCK Act ranges, not fills.
RSS for Sara BaileyNew filings for this member, by filing date.
Educated guesstimate only. Filings report ranges, not exact sizes. Share counts use the range midpoint (or 1.5× the floor for “Over $X”) and the closing price on the trade date. Open lots are marked to the latest Yahoo Finance close. Cash dividends and split factors are applied while a reconstructed lot is open. Sales with no matching disclosed buy are treated as closing an unseen lot at the sale price (about $0 P/L on that slice). Bonds and rows without a usable ticker are excluded. This is not actual profit.